register

News & Trends - MedTech & Diagnostics

Grattan report ‘pea and thimble’ trick for private health insurance

Health Industry Hub | December 9, 2019 |

The latest proposals from the Grattan Institute suggesting changes to community rating for private health insurance amount to no more than a complex “pea and thimble” trick that on the authors own admission, will result in older Australian’s paying more for their health insurance.

The newly released: ‘Saving private health 2: Making private health insurance viable’ claims to offer solutions to save private health insurance, but would actually do damage, says Australian Private Hospitals Association (APHA) CEO Michael Roff.

“By allowing health insurers to risk rate insurance for those under 55, anyone in this age group who has a chronic health condition, has previously had surgery or who has a history of mental health issues would effectively be priced out of the private insurance market, throwing even more demand on the overburdened public hospital system.

“The proposals rely on illusory savings from the report released last week, when the report authors calculated billions of dollars of savings based on reducing bed days for private patients – ignoring the fact the overwhelmingly private hospitals are paid per episode, not per day.

You may also like Novel Australian labs to revolutionise STEMM innovation.

“This report merely compounds the errors and misunderstandings of the private health sector the authors were so keen to talk about last week.

Mr Roff said there is, however, room for improvement in the current system.

“We have a set of policy measures for private health insurance (the private health insurance rebate, lifetime health cover and the medicare levy surcharge) that have been effective over time, but are now 20 years old. The Australian health system as a whole would benefit from some sensible adjustments to these policies to ensure they are relevant in today’s environment.

“The Grattan Institute’s complex and convoluted proposals would damage both the public and private health systems,” he said.

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.


News & Trends - Pharmaceuticals

Federal court dismisses Arrotex dispute against Health Minister

Federal court dismisses Arrotex dispute against Health Minister

Health Industry Hub | July 12, 2024 |

Pharma News: The Federal Court has ruled against Arrotex Pharmaceuticals in their bid to challenge the Minister for Health and […]

More


News & Trends - Pharmaceuticals

Largest diabetes study reveals major benefits of dual therapy with SGLT2 inhibitors and GLP1 receptor agonists

Largest diabetes study reveals major benefits of SGLT2 inhibitors and GLP1 receptor agonists dual therapy

Health Industry Hub | July 12, 2024 |

Pharma News: Combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to […]

More


News & Trends - Pharmaceuticals

Queensland opens first regional CAR T-cell treatment centre

Queensland launches first regional CAR T-cell treatment centre

Health Industry Hub | July 12, 2024 |

Pharma News: Gilead Sciences and Lymphoma Australia have welcomed the opening of Australia’s first regional CAR T-cell treatment centre at […]

More


News & Trends - Pharmaceuticals

Government inaction leaves essential medicine shortages unresolved

Government inaction leaves essential medicine shortages unresolved

Health Industry Hub | July 12, 2024 |

Pharma News: Over the past 12 months, at least six essential medications and products have been withdrawn from the Australian […]

More


This content is copyright protected. Please subscribe to gain access.